NO944093L - Lineære adhesjonsinhibitorer - Google Patents

Lineære adhesjonsinhibitorer

Info

Publication number
NO944093L
NO944093L NO944093A NO944093A NO944093L NO 944093 L NO944093 L NO 944093L NO 944093 A NO944093 A NO 944093A NO 944093 A NO944093 A NO 944093A NO 944093 L NO944093 L NO 944093L
Authority
NO
Norway
Prior art keywords
disorders
adhesion inhibitors
linear adhesion
linear
aiibss3
Prior art date
Application number
NO944093A
Other languages
English (en)
Other versions
NO944093D0 (no
Inventor
Alfred Jonczyk
Brunhilde Felding-Habermann
Beate Diefenbach
Friedrich Rippmann
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO944093D0 publication Critical patent/NO944093D0/no
Publication of NO944093L publication Critical patent/NO944093L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrane Compounds (AREA)
  • Optical Fibers, Optical Fiber Cores, And Optical Fiber Bundles (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Lineære peptider med formel I I, hvor X er H eller Ac; A mangler eller er Asp eller et peptidfragment valgt fra en gruppe bestående av Ala- Asp, Thr-Ala-Asp, Lys-Thr-Ala-Asp, Lys-Thr- Ala-Asn, Lys-Thr-Gly-Asp, Lys-Ala-Ala- Asp, Arg-Thr-Ala-Asp, Ser-Ala-Asp, Gln- Ser-Ala-Asp, Gly-Lys-Thr-Ala-Asp, Asn- Gly-Lys-Thr-Ala-Asp, Ile-Ser-Ala-Gly, Arg-Ser-Ala-Gly, Cys-Asn-Gly-Lys-Thr- Ala-Asp, Tyr-Cys-Asn-Gly-Lys-Thr-Ala- Asp , Asp-Tyr-Cys-Asn-Gly-Lys-Thr-Ala- Asp, Gly-Lys-Thr-Cys-Asp, Asp-Asp-Tyr- Cys-Asn-Gly- Lys-Thr-Ala-Asp, Gly-Lys- Thr-Cys(Trt)-Asp, Met-Asp-Asp-Tyr-Cys- Asn-Gly-Lys-Thr-Ala-Asp og Asp-Met-Asp- Asp-Tyr-Cys-Asn-Gly-Lys-Thr-Ala-Asp; B mangler eller er Ala, Arg, Asn, Asp, Cys, Gin, Glu, Gly, His, Ile, Leu, Lys, Met, Orn, Phe, 4-Hal-Phe, Pro, Ser, Thr, Trp, Tyr, Val eller et N-metylert derivat av de nevnte aminosyrerester, eller et peptidfragment valgt fra en gruppe bestående av Pro-Arg, Pro- Arg - Asn, Pro-Arg -Asn-Pro, Pro-Arg-Asn-Pro- His, Pro-Arg-Asn-Pro-His-Lys, Pro-Arg- Asn-Pro-His-Lys-Gly, Pro-Arg-Asn-Pro- His-Lys-Gly-Pro, Pro-Arg-Asn-Pro-His- Lys-Gly-Pro-Ala og Pro-Arg-Asn-Pro-His- Lys-Gly-Pro-Ala-Thr, idet bare en av restene A og B kan mangle; Z er OH, OR2, NH2, NHR2 eller N(R2)2; R1 er H, R2, Trt, Dpm eller Bzl; R2 er alkyl med 1- 6 C-atomer; Hal er F, Cl, Br eller I; og Ac er alkanoyl med 1-10 C-atomer, aralkanoyl med 8-10 C-atomer eller aroyl med 7-11 C-atomer; samt fysio- logisk akseptable salter derav, er virkningsfulle inhibitorer for bindingen av blodplateintegrinet GP IlbZIIa (allbp3) til naturlige ligander, og egner seg blant annet til profylakse og til behandling av sykdommer i blod- omløpet, ved trombose, hjerteinfarkt, koronare hjertesykdommer, arterio- og atherosklerose, tumorer, osteolytiske sykdommer og virker understøttende på sårhelingsprosessen.
NO944093A 1993-10-28 1994-10-27 Lineære adhesjonsinhibitorer NO944093L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4336758A DE4336758A1 (de) 1993-10-28 1993-10-28 Lineare Adhäsionsinhibitoren

Publications (2)

Publication Number Publication Date
NO944093D0 NO944093D0 (no) 1994-10-27
NO944093L true NO944093L (no) 1995-05-02

Family

ID=6501202

Family Applications (1)

Application Number Title Priority Date Filing Date
NO944093A NO944093L (no) 1993-10-28 1994-10-27 Lineære adhesjonsinhibitorer

Country Status (16)

Country Link
US (1) US5747457A (no)
EP (1) EP0655462B1 (no)
JP (1) JPH07149794A (no)
KR (1) KR950011466A (no)
CN (1) CN1107159A (no)
AT (1) ATE165837T1 (no)
AU (1) AU690923B2 (no)
CA (1) CA2134418A1 (no)
CZ (1) CZ265594A3 (no)
DE (2) DE4336758A1 (no)
HU (1) HUT69179A (no)
NO (1) NO944093L (no)
PL (1) PL305632A1 (no)
RU (1) RU94039288A (no)
SK (1) SK130094A3 (no)
ZA (1) ZA948479B (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9801716A (es) * 1995-08-30 1998-05-31 Searle & Co Derivados de meta-guanidina, urea, tiourea o acido aminobenzoico azaciclico, como antagonistas de integrina.
US6100423A (en) * 1995-08-30 2000-08-08 G. D. Searle & Co. Amino benzenepropanoic acid compounds and derivatives thereof
DE19534016A1 (de) * 1995-09-14 1997-03-20 Merck Patent Gmbh Biotinderivate
WO2000038715A2 (en) 1998-12-23 2000-07-06 G.D. Searle & Co. Use of an integrin antagonist and radiation in the treatment of neoplasia
ES2436170T3 (es) * 2003-12-03 2013-12-27 The Scripps Research Institute Anticuerpos y péptidos específicos de la integrina alfa II beta3
CN108203465B (zh) * 2016-12-20 2022-09-02 山西医科大学 一种双重靶向抑制肿瘤细胞和肿瘤血管且性质稳定的多肽

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2799670A (en) * 1954-04-13 1957-07-16 Laufer Louis Method of preparing cysteinylglycine
US4177277A (en) * 1977-01-17 1979-12-04 E. R. Squibb & Sons, Inc. Method for alleviating hypertension
JP2945680B2 (ja) * 1988-09-09 1999-09-06 旭硝子株式会社 ペプチド誘導体およびその用途
CA2009613A1 (en) * 1989-02-09 1990-08-09 Victor M. Garsky Polypeptide synthesis
AU5939890A (en) * 1989-06-07 1991-01-07 Genentech Inc. Platelet aggregation inhibitors and related molecules

Also Published As

Publication number Publication date
CA2134418A1 (en) 1995-04-29
HUT69179A (en) 1995-08-28
SK130094A3 (en) 1995-05-10
HU9403100D0 (en) 1994-12-28
PL305632A1 (en) 1995-05-02
AU690923B2 (en) 1998-05-07
ATE165837T1 (de) 1998-05-15
US5747457A (en) 1998-05-05
DE4336758A1 (de) 1995-05-04
CZ265594A3 (en) 1995-07-12
CN1107159A (zh) 1995-08-23
RU94039288A (ru) 1996-09-10
ZA948479B (en) 1995-06-20
EP0655462A1 (de) 1995-05-31
EP0655462B1 (de) 1998-05-06
JPH07149794A (ja) 1995-06-13
DE59405893D1 (de) 1998-06-10
KR950011466A (ko) 1995-05-15
AU7750194A (en) 1995-05-18
NO944093D0 (no) 1994-10-27

Similar Documents

Publication Publication Date Title
RU94031102A (ru) Сульфамиды в качестве антагонистов эндотелина и способ лечения соответствующих заболеваний
ATE207355T1 (de) Behandlung von hyperproliferativen gefässerkrankungen
DE68913667D1 (de) Imidazole für die Behandlung von Atherosclerose.
DE69429160D1 (de) Behandlung von textilprodukt
ATE145136T1 (de) Verwendung von ketoconazol und ein retinoid zur behandlung der akne vulgaris
TR199901962T2 (xx) Bisiklik amino asitler.
DK465488A (da) Farmaceutisk praeparat indeholdende en triazol-forbindelse
NO944093D0 (no) Lineære adhesjonsinhibitorer
DE69110937D1 (de) Herzschrittmacher zur Beendung von Herzarrhythmia.
EP0302595A3 (en) Pinacidil for treatment of pulmonary hypertension or right heart failure
ATE100716T1 (de) Verwendung von ace-inhibitoren gegen neointimabildung nach gefaessverletzung.
DE69121104D1 (de) Frequenzadaptierender herzschrittmacher
DE68911776D1 (de) Konjugierte Oxybutenolide zur Behandlung von Ulcera.
SE8301004D0 (sv) Pyridinforeningar
DE68912670D1 (de) Behandlung von Celluloseblättern.
CA2185394A1 (en) Biotinderivate
ATE218856T1 (de) Aminotetralinderivat zur behandlung von herzkreislauferkrankung
IT1221667B (it) Macchina per la produzione di sottopiedi e/o altri articoli termoformati
DE3888228D1 (de) Bakterienzellulose für die Oberflächenbehandlung von Faserbahnen.
GR852408B (no)
DE69522685D1 (de) Behandlung von blut-plasma
DE69636814D1 (de) Verwendung des menschlichen choriongonadotropins in der behandlung von kaposi's-sarcoma
RU93015924A (ru) Способ лечения трофических язв нижних конечностей
JPS6490158A (en) 1,2-diamino compound, manufacture and medicine for treating cardiac disease and circulatory disease
ATE96330T1 (de) Heilen von wunden.